Compare YRD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YRD | EDIT |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.8M | 233.3M |
| IPO Year | 2015 | 2016 |
| Metric | YRD | EDIT |
|---|---|---|
| Price | $4.31 | $2.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 77.2K | ★ 1.6M |
| Earning Date | 11-25-2025 | 11-10-2025 |
| Dividend Yield | ★ 10.16% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.03 | N/A |
| Revenue | ★ $872,820,262.00 | $46,383,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.14 | ★ N/A |
| Revenue Growth | ★ 10.41 | N/A |
| 52 Week Low | $4.15 | $0.91 |
| 52 Week High | $8.74 | $4.54 |
| Indicator | YRD | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 32.67 | 41.82 |
| Support Level | $4.27 | $2.40 |
| Resistance Level | $4.44 | $2.70 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 20.84 | 45.90 |
Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.